Q-omics provides the consensus-scored MAZ profile across patient tissues and cancer cell-line models. MAZ expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAZ is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MAZ protein abundance shows 26,349 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where MAZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAZ survival associations across molecular data types. MAZ RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAZ RNA expression–survival associations across cancer types. High MAZ expression shows unfavorable associations in ACC, KIRP, LIHC, MESO and LUSC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAZ RNA expression.
This table summarizes MAZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAZ shows higher tumor expression in HNSC, KIRC, KIRP, LIHC, LUSC and STAD. The HNSC box plot shows higher MAZ RNA expression in tumor versus normal tissue (log2 FC = +1.280, t-test p < 0.001).
This table shows molecular features associated with MAZ in patient tissues and cancer cell lines. In patient samples, MAZ shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
